22 completed, 8 terminated, 2 unknown, 1 active not recruiting. 34 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 34 | Completed 22, Terminated 8, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 7, Terminated 4 |
Follow Polymerase Chain Reaction: new trials by email Literature Review of Polymerase Chain Reaction trials Research Report on Polymerase Chain Reaction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2012-03-01 | 2014-04-21 |
| Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer sirolimus, gold sodium thiomalate, pharmacological study - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 1 | Withdrawn | Mayo Clinic | 2011-06-01 | 2020-04-01 | |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia entinostat, imatinib mesylate, laboratory biomarker analysis - Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2010-10-01 | 2017-08-08 |
| Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors pralatrexate, fluorouracil, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Nebraska | 29 | 2010-09-14 | 2023-12-26 |
| A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas flucytosine, polymerase chain reaction, immunohistochemistry staining method - Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma | Phase 1 | Completed | City of Hope Medical Center | 15 | 2010-08-01 | 2017-11-09 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer lenalidomide, cetuximab, mutation analysis - Colon Cancer, Rectal Cancer | Phase 1 | Terminated | Case Comprehensive Cancer Center | 3 | 2009-10-01 | 2012-03-20 |
| Vaccine Therapy in Preventing HPV in HIV-Positive Women in India quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, DNA analysis, polymerase chain reaction - Cervical Cancer, Nonneoplastic Condition | Phase 1 | Completed | AIDS Malignancy Consortium | 150 | 2009-08-01 | 2024-03-19 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer bevacizumab, FOLFOX regimen, fluorouracil - Colorectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 11 | 2009-03-11 | 2025-06-22 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, cyclophosphamide, biopsy - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2009-02-01 | 2017-04-19 |
| PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction - Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | AIDS Malignancy Consortium | 17 | 2008-09-01 | 2018-06-06 |
| Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes - Cancer | Phase 1 | Unknown | Milton S. Hershey Medical Center | 20 | 2008-08-01 | 2013-12-18 |
| Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma rituximab, clofarabine, DNA methylation analysis - Lymphoma | Phase 1 / Phase 2 | Terminated | OHSU Knight Cancer Institute | 2 | 2008-05-01 | 2019-11-27 |
| Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia imatinib mesylate, panobinostat, polymerase chain reaction - Leukemia | Phase 1 | Completed | City of Hope Medical Center | 9 | 2008-05-01 | 2014-08-15 |
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer PEG-interferon alfa-2b, Sorafenib, gene expression analysis - Kidney Cancer | Phase 1 | Terminated | Thomas Olencki | 1 | 2008-02-01 | 2015-06-08 |
| Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery DNA analysis, DNA methylation analysis, RNA analysis - Prostate Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 1045 | 2007-11-26 | 2026-08-20 |
| Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma rituximab, bortezomib, carboplatin - Lymphoma | Phase 1 | Completed | AIDS Malignancy Consortium | 23 | 2007-11-01 | 2020-08-10 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-10-01 | 2015-03-31 |
Showing 20 of 34. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Follicular (7) · Lymphoma, Mantle-Cell (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Melanoma (6) · Burkitt Lymphoma (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Large-Cell, Immunoblastic (5) · Lymphoma, Non-Hodgkin (5) · Congenital Abnormalities (4) · Lymphoma (4) · Waldenstrom Macroglobulinemia (4) · Colonic Neoplasms (3) · Leukemia (3)
Fred Hutchinson Cancer Center (7) · City of Hope Medical Center (5) · AIDS Malignancy Consortium (3) · Case Comprehensive Cancer Center (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · University of Nebraska (2) · Cancer Research UK (1) · Cytheris SA (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Milton S. Hershey Medical Center (1) · OHSU Knight Cancer Institute (1) · Thomas Olencki (1)
United States (29) · Belgium (1) · India (1) · United Kingdom (1)
Cassian Yee (2) · Kenneth G. Lucas, MD (2) · Sylvia Lee (2) · Ahmad Awada, MD, PhD (1) · Ajay Gopal (1) · Andrew D. Zelenetz, MD, PhD (1) · Aude Chapuis (1) · Brian Till (1) · Craig Okada, MD, PhD (1) · Elizabeth C. Reed, MD (1) · Erin G. Reid, MD (1) · Helen K. Chew, MD (1) · Jana Portnow (1) · Jean Grem (1) · Joel Palefsky, MD (1)
PMID 20400682, PMID 22308288, PMID 22989664, PMID 24530971, PMID 26242208, PMID 27269940, PMID 30573564, PMID 30773077
P30CA033572 (4), K12CA076930 (3), U01CA121947 (3), P01CA018029 (1), P01CA023766 (1), P01CA044991 (1), P30CA008748 (1), P30CA036727 (1), P30CA069533 (1), P30CA093373 (1), R01CA102521 (1), R21CA128283 (1), R21CA137647 (1), U01CA062490 (1), U01CA070095 (1)